November 24, 2016 - By Darrin Black · 0 Comments
The stock of Aptevo Therapeutics Incorporated (NASDAQ:APVO) registered a decrease of 2.93% in short interest. APVO’s total short interest was 762,200 shares in November as published by FINRA. Its down 2.93% from 785,200 shares, reported previously. With 130,500 shares average volume, it will take short sellers 6 days to cover their APVO’s short positions. The short interest to Aptevo Therapeutics Incorporated’s float is 4.66%. The stock decreased 0.98% or $0.02 on November 23, hitting $2.02. About 126,945 shares traded hands. Aptevo Therapeutics Inc (NASDAQ:APVO) has risen 6.00% since October 25, 2016 and is uptrending. It has outperformed by 0.59% the S&P500.
Aptevo Therapeutics Inc. is a biotechnology company. The company has a market cap of $41.10 million. The Firm focuses on oncology and hematology (blood disease) therapeutics to manage patients’ lives. It currently has negative earnings. The Company’s segment is engaged in the discovery, development, commercialization and sale of sale oncology and hematology therapeutics.
Aptevo Therapeutics Inc. is a biotechnology company. The Firm focuses on oncology (cancer) and hematology (blood disease) therapeutics to manage patientsâ€™ lives. The Companyâ€™s segment is engaged in the discovery, development, commercialization and sale of sale oncology and hematology therapeutics. The Companyâ€™s core technology is the ADAPTIR (modular protein technology) platform. The Firm has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Companyâ€™s investigational-stage product candidates MOR209/ES414, ES210, ES425 and otlertuzumab are built on its ADAPTIR (modular protein technology) platform. The technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The mechanisms of action for MOR209/ES414, ES210, ES425 and otlertuzumab include redirected T-cell cytotoxicity (RTCC), by which a therapeutic molecule brings T-cells into contact with tumor cells and trigger tumor killing, or targeted delivery of cytokines (or immune modulating protein) to diseased cells. The structural differences of ADAPTIR molecules over monoclonal antibodies allow for the development of new ADAPTIR immunotherapeutics that engage disease targets in a manner and produce a signaling response. It provides product candidate generation, validation and pre-clinical and clinical development using the ADAPTIR platform.
More notable recent Aptevo Therapeutics Inc (NASDAQ:APVO) news were published by: Globenewswire.com which released: “Aptevo Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare …” on November 23, 2016, also Businesswire.com with their article: “Aptevo Therapeutics Completes Separation from Emergent BioSolutions” published on August 01, 2016, Quotes.Wsj.com published: “News Aptevo Therapeutics Inc.APVO” on July 24, 2016. More interesting news about Aptevo Therapeutics Inc (NASDAQ:APVO) were released by: Globenewswire.com and their article: “Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 …” published on July 15, 2016 as well as Schaeffersresearch.com‘s news article titled: “Analyst Update: Aptevo Therapeutics Inc, PBF Energy Inc, and Cyberark Software Ltd” with publication date: September 09, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black